With chance to take on Bristol Myers’ $13B heart drug, Cytokinetics preps for pivotal studies with $450M debt raise

As Cytokinetics traded near its one-year high earlier this week, execs decided to take on a load of debt. But investors aren’t liking what they’ve seen.

The San Francisco biotech announced after market close Wednesday that it would raise $450 million in debt in the form of a convertible senior…